Evidence map›Paper›PMID 36284930›Full record

ArticleTransplantation direct2022

Magnetic Resonance Imaging Predictors of Hepatocellular Carcinoma Progression and Dropout in Patients in Liver Transplantation Waiting List.

Azarakhsh Baghdadi, Harry T Luu, Mohammadreza Shaghaghi, Maryam Ghadimi, Cem Simsek, Ziyi Xu, Bita Hazhirkarzar, Mina Motaghi, Muhammad Hammami, Jeanne M Clark and 3 more

Abstract read
In one paragraph

Article in Transplantation direct, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Azarakhsh BaghdadiDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Harry T LuuDepartment of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Mohammadreza ShaghaghiDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Maryam GhadimiDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Cem SimsekBrigham and Women's Hospital, Division of Gastroenterology, Boston, MA.
Ziyi XuDepartment of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Bita HazhirkarzarDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Mina MotaghiDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Muhammad HammamiUniversity of Maryland Medical Center, Division of Gastroenterology and Hepatology, Baltimore, MD.
Jeanne M ClarkDepartment of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Ahmet GurakarDepartment of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Ihab R KamelDepartment of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Amy K KimDepartment of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

Improved early prognostic algorithm for hepatocellulcar carcinomaK08CA237624 · NCI · JOHNS HOPKINS UNIVERSITY · PI KIM, AMY K · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA237624
6 · The paper itself

Abstract

With the rising incidence of hepatocellular carcinoma (HCC), more patients are now eligible for liver transplantation. Consequently, HCC progression and dropout from the waiting list are also anticipated to rise. We developed a predictive model based on radiographic features and alpha-fetoprotein to identify high-risk patients. Methods: This is a case-cohort retrospective study of 76 patients with HCC who were listed for liver transplantation with subsequent liver transplantation or delisting due to HCC progression. We analyzed imaging-based predictive variables including tumor margin (well- versus ill-defined), capsule bulging lesions, volumetric analysis and distance to portal vein, tumor numbers, and tumor diameter. Volumetric analysis of the index lesions was used to quantify index tumor total volume and volumetric enhancement, whereas logistic regression and receiver operating characteristic curve (ROC) analyses were used to predict the main outcome of disease progression. Results: In univariate analyses, the following baseline variables were significantly associated with disease progression: size and number of lesions, sum of lesion diameters, lesions bulging the capsule, and total and venous-enhancing (viable) tumor volumes. Based on multivariable analyses, a risk model including lesion numbers and diameter, capsule bulging, tumor margin (infiltrative versus well-defined), and alpha-fetoprotein was developed to predict HCC progression and dropout. The model has an area under the ROC of 82%, which was significantly higher than Milan criteria that has an area under the ROC of 67%. Conclusions: Our model has a high predictive test for patient dropout due to HCC progression. This model can identify high-risk patients who may benefit from more aggressive HCC treatment early after diagnosis to prevent dropout due to such disease progression.

Identifiers

PMID36284930
PMCPMC9584197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.